Signals, Powered By EquityPandit
Zydus Cadila has received final approval to market topiramate extended release capsules, from the US health regulator. It is used for treating seizures and migraine.
In a BSE filing Zydus Cadila stated that, it has received approval from the US Food and Drug Administration (USFDA) to market the drug in strengths of 25 mg, 50 mg and 100 mg.
Further it added that, the drug will be manufactured at the group’s manufacturing facility at Moraiya, Ahmedabad.
